Tvardi Therapeutics (TVRD) Stock: Why It's Up Today
Updated Oct 20, 2026, 1:16 PM ET · intraday price
- Trading at $1.04 as of 1:16 PM ET, +7.22% vs the prior close of $0.97.
- Volume 118.05K shares, 0.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Pfizer (PFE)
TVRD jumps 7.2% to $1.04. Trading at $1.04 (intraday, 1:16 PM ET), +7.22% vs the prior close of $0.97. Day range $0.97–$1.08, opened at $1.03.
TVRD daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 20, 2026 — TVRD jumps 7.2% to $1.04
- Trading at $1.04 (intraday, 1:16 PM ET), +7.22% vs the prior close of $0.97. Day range $0.97–$1.08, opened at $1.03.
- Volume was 118.05K shares, 0.6x its 50-day average of 185.07K.
- Price is -32.0% vs its 50-day average ($1.53) and -64.1% vs its 200-day average ($2.90).
- 52-week range $0.93–$6.43; the current price sits at 2% of that range, 83.8% below the 52-week high.
Oct 19, 2026 — TVRD slides 4.0% to $0.97, a 52-week low
- Closed at $0.97, -3.96% vs the prior close of $1.01. Day range $0.97–$1.03, opened at $1.01.
- Volume was 201.34K shares, 1.1x its 50-day average of 183.12K.
- Price is -37.2% vs its 50-day average ($1.54) and -66.7% vs its 200-day average ($2.91).
- 52-week range $0.93–$6.65; today's close sits at 1% of that range, 85.4% below the 52-week high.
Oct 16, 2026 — TVRD slides 5.6% to $1.01
- Closed at $1.01, -5.61% vs the prior close of $1.07. Day range $1.00–$1.06, opened at $1.05.
- Volume was 91.72K shares, 0.5x its 50-day average of 191.68K — lighter than usual.
- Price is -35.3% vs its 50-day average ($1.56) and -65.5% vs its 200-day average ($2.93).
- 52-week range $0.93–$7.23; today's close sits at 1% of that range, 86.0% below the 52-week high.
Oct 15, 2026 — TVRD jumps 7.0% to $1.07
- Closed at $1.07, +7.00% vs the prior close of $1.00. Day range $1.00–$1.07, opened at $1.03.
- Volume was 94.00K shares, 0.5x its 50-day average of 196.51K — lighter than usual.
- Price is -32.2% vs its 50-day average ($1.58) and -63.6% vs its 200-day average ($2.94).
- 52-week range $0.93–$7.23; today's close sits at 2% of that range, 85.2% below the 52-week high.
Oct 14, 2026 — TVRD slides 3.8% to $1.00, a 52-week low
- Closed at $1.00, -3.85% vs the prior close of $1.04. Day range $0.99–$1.03, opened at $1.01.
- Volume was 75.70K shares, 0.4x its 50-day average of 202.87K — lighter than usual.
- Price is -37.4% vs its 50-day average ($1.60) and -66.2% vs its 200-day average ($2.96).
- 52-week range $0.93–$7.23; today's close sits at 1% of that range, 86.2% below the 52-week high.
Oct 13, 2026 — TVRD dips 1.9% to $1.04
- Closed at $1.04, -1.89% vs the prior close of $1.06. Day range $1.01–$1.06, opened at $1.06.
- Volume was 73.40K shares, 0.4x its 50-day average of 205.72K — lighter than usual.
- Price is -35.7% vs its 50-day average ($1.62) and -65.0% vs its 200-day average ($2.98).
- 52-week range $0.93–$7.23; today's close sits at 2% of that range, 85.6% below the 52-week high.
Oct 12, 2026 — TVRD rises 2.9% to $1.06
- Closed at $1.06, +2.91% vs the prior close of $1.03. Day range $0.97–$1.08, opened at $1.02.
- Volume was 248.10K shares, 1.2x its 50-day average of 204.47K.
- Price is -35.3% vs its 50-day average ($1.64) and -64.6% vs its 200-day average ($2.99).
- 52-week range $0.93–$43.65; today's close sits at 0% of that range, 97.6% below the 52-week high.
Oct 9, 2026 — TVRD slides 4.6% to $1.03, a 52-week low
- Closed at $1.03, -4.63% vs the prior close of $1.08. Day range $1.02–$1.09, opened at $1.09.
- Volume was 130.30K shares, 0.6x its 50-day average of 208.49K.
- Price is -37.9% vs its 50-day average ($1.66) and -65.7% vs its 200-day average ($3.00).
- 52-week range $0.93–$43.65; today's close sits at 0% of that range, 97.6% below the 52-week high.
Oct 8, 2026 — TVRD dips 1.8% to $1.08
- Closed at $1.08, -1.82% vs the prior close of $1.10. Day range $1.04–$1.10, opened at $1.10.
- Volume was 159.90K shares, 0.7x its 50-day average of 218.47K.
- Price is -35.7% vs its 50-day average ($1.68) and -64.2% vs its 200-day average ($3.02).
- 52-week range $0.93–$43.65; today's close sits at 0% of that range, 97.5% below the 52-week high.
Oct 7, 2026 — TVRD rises 1.9% to $1.10
- Closed at $1.10, +1.85% vs the prior close of $1.08. Day range $1.04–$1.11, opened at $1.08.
- Volume was 136.50K shares, 0.6x its 50-day average of 229.00K — lighter than usual.
- Price is -35.3% vs its 50-day average ($1.70) and -63.7% vs its 200-day average ($3.03).
- 52-week range $0.93–$43.65; today's close sits at 0% of that range, 97.5% below the 52-week high.
Oct 6, 2026 — TVRD slides 5.3% to $1.08, 6 down days in a row
- Closed at $1.08, -5.26% vs the prior close of $1.14. Day range $1.07–$1.18, opened at $1.15.
- Volume was 148.30K shares, 0.6x its 50-day average of 254.46K — lighter than usual.
- Price is -37.5% vs its 50-day average ($1.73) and -64.6% vs its 200-day average ($3.05).
- 52-week range $0.93–$43.65; today's close sits at 0% of that range, 97.5% below the 52-week high.
- That makes 6 straight losses.
Oct 5, 2026 — TVRD dips 0.9% to $1.14, 5 down days in a row
- Closed at $1.14, -0.87% vs the prior close of $1.15. Day range $1.12–$1.17, opened at $1.17.
- Volume was 148.30K shares, 0.6x its 50-day average of 258.21K — lighter than usual.
- Price is -35.1% vs its 50-day average ($1.76) and -62.8% vs its 200-day average ($3.06).
- 52-week range $0.93–$43.65; today's close sits at 0% of that range, 97.4% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — TVRD slides 7.3% to $1.15, 4 down days in a row
- Closed at $1.15, -7.26% vs the prior close of $1.24. Day range $1.13–$1.28, opened at $1.25.
- Volume was 313.80K shares, 1.2x its 50-day average of 261.89K.
- Price is -35.6% vs its 50-day average ($1.78) and -62.6% vs its 200-day average ($3.08).
- 52-week range $0.93–$43.65; today's close sits at 1% of that range, 97.4% below the 52-week high.
- That makes 4 straight losses.
TVRD bull case vs bear case (from the data)
- No clear positive signal in the price trend, filings or insider data right now.
- Price is -32.0% vs its 50-day average — short-term trend is down.
- Price is -64.1% vs its 200-day average — below the long-term trend line.
- Annual revenue fell 66.0% in the latest fiscal year (SEC XBRL).
- Latest fiscal-year net income: loss of $18.21M.
- Share count up 42.2% in a year (dilution).
- High volatility: average daily move of 6.1% over 20 sessions.
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
TVRD latest news & SEC filings
Every SEC filing by or about TVRD in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$6.46M (prior year $4.17M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.69 (prior year -$1.00) (loss narrowed vs Jun 30, 2025)
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jul 17, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade TVRD
- Last results release: Aug 14, 2026 (8-K Item 2.02). Previous ones: May 8, 2026, Mar 31, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 6.06% (largest 19.8%). That is a volatile stock.
- Liquidity: about 239.41K shares (≈$248.99K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.04 vs a range of $0.93–$6.43 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:3 on Apr 16, 2025, 1:12 on Dec 31, 2024
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 10-Q Aug 14, 2026; 8-K Aug 14, 2026; 8-K Jul 30, 2026.
- Share count: 13.34M shares outstanding (Aug 11, 2026), +42.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
TVRD market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | 1.03 | 1.08 | 0.97 | 1.04 | 118.05K |
| Oct 19, 2026 | 1.01 | 1.03 | 0.97 | 0.97 | 201.30K |
| Oct 16, 2026 | 1.05 | 1.07 | 1.00 | 1.01 | 91.80K |
| Oct 15, 2026 | 1.03 | 1.07 | 1.00 | 1.07 | 94.00K |
| Oct 14, 2026 | 1.01 | 1.03 | 0.99 | 1.00 | 75.70K |
| Oct 13, 2026 | 1.06 | 1.06 | 1.01 | 1.04 | 73.40K |
| Oct 12, 2026 | 1.02 | 1.08 | 0.97 | 1.06 | 248.10K |
| Oct 9, 2026 | 1.09 | 1.09 | 1.02 | 1.03 | 130.30K |
| Oct 8, 2026 | 1.10 | 1.10 | 1.04 | 1.08 | 159.90K |
| Oct 7, 2026 | 1.08 | 1.11 | 1.04 | 1.10 | 136.50K |
| Oct 6, 2026 | 1.15 | 1.18 | 1.07 | 1.08 | 148.30K |
| Oct 5, 2026 | 1.17 | 1.17 | 1.12 | 1.14 | 148.30K |
| Oct 2, 2026 | 1.25 | 1.28 | 1.13 | 1.15 | 313.80K |
| Oct 1, 2026 | 1.25 | 1.31 | 1.21 | 1.24 | 332.60K |
| Sep 30, 2026 | 1.29 | 1.32 | 1.20 | 1.25 | 232.70K |
| Sep 29, 2026 | 1.32 | 1.42 | 1.26 | 1.28 | 254.10K |
| Sep 28, 2026 | 1.27 | 1.37 | 1.19 | 1.33 | 351.30K |
| Sep 25, 2026 | 1.14 | 1.28 | 1.07 | 1.27 | 656.60K |
| Sep 24, 2026 | 1.30 | 1.33 | 0.93 | 1.06 | 609.40K |
| Sep 23, 2026 | 1.59 | 1.61 | 1.25 | 1.32 | 412.10K |
About Tvardi Therapeutics
Tvardi Therapeutics (TVRD) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SUGAR LAND, TX. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1346830.
TVRD board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Imran Nizamudin Alibhai | Chief Executive Officer | Feb 2, 2026 |
| Wallace L Jr Hall | Director | Jun 11, 2026 |
| Sujal Shah | Director | Jun 11, 2026 |
| Susan Ph.D. Shiff | Director | Jun 11, 2026 |
| Cynthia Smith | Director | Jun 11, 2026 |
| Michael S Wyzga | Director | Jun 11, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Imran Nizamudin Alibhai | Chief Executive Officer | Feb 2, 2026 |
| Avi Daniel Conn | Chief Financial Officer | Feb 2, 2026 |
| John Saewook M.D. Kauh | Chief Medical Officer | Feb 2, 2026 |
| Stephen Paul O'Brien | Principal Accounting Officer | Feb 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
TVRD financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-18.21M | -3.26 | $-23.50M |
| Dec 31, 2024 | $7.14M | $-29.40M | -11.42 | $-18.30M |
| Dec 31, 2023 | $20.97M | $-118.51M | -26.26 | $-92.08M |
| Dec 31, 2022 | $41.87M | $-85.47M | -19.12 | $-78.73M |
| Dec 31, 2021 | $23.03M | $-88.44M | -1.74 | $-60.09M |
Latest balance sheet: total assets $17.52M, total liabilities $9.13M, cash $15.77M (as of Jun 30, 2026).
TVRD earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 14, 2026 | 8-K Item 2.02 (results) | $1.90 |
| May 8, 2026 | 8-K Item 2.02 (results) | $4.18 |
| Mar 31, 2026 | 8-K Item 2.02 (results) | $3.18 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $4.11 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $23.79 |
| May 13, 2025 | 8-K Item 2.02 (results) | $26.54 |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
| Mar 4, 2024 | 8-K Item 2.02 (results) | — |
| Nov 13, 2023 | 8-K Item 2.02 (results) | — |
| Aug 7, 2023 | 8-K Item 2.02 (results) | — |
| May 15, 2023 | 8-K Item 2.02 (results) | — |
| Mar 6, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)United Therapeutics (UTHR)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Space Exploration Technologies (SPCX)Tesla (TSLA)Sandisk (SNDK)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on TVRD
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: intraday data as of Oct 20, 2026, 1:16 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.